Spektus Pharma, a Quebec-based specialty pharma company developing therapeutics for the treatment of CNS disorders, has entered into a strategic partnership with Sweden-based contract development and manufacturing organization (CDMO) Recipharm.
The companies will jointly develop and supply a portfolio of CNS focused products in a partnership that will use Spektus’ Flexitab oral drug delivery platform to create flexible, breakable extended-release tablets for key global markets, including the USA, Canada, Europe, the UK and Brazil.
Spektus’ expertise in formulation development will be combined with Recipharm’s extensive manufacturing capabilities, regulatory excellence and robust global supply chain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze